menu
{ "item_title" : "Addressing the Barriers to Pediatric Drug Development", "item_author" : [" Institute of Medicine", "Board on Health Sciences Policy", "Forum on Drug Discovery Development and "], "item_description" : "Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children--50 to 75 percent--have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.", "item_img_path" : "https://covers3.booksamillion.com/covers/bam/0/30/910/742/0309107423_b.jpg", "price_data" : { "retail_price" : "29.00", "online_price" : "29.00", "our_price" : "29.00", "club_price" : "29.00", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : "" } }
Addressing the Barriers to Pediatric Drug Development|Institute of Medicine

Addressing the Barriers to Pediatric Drug Development : Workshop Summary

local_shippingShip to Me
Earliest ship date: September 7, 2026
FREE Shipping for Club Members help

Overview

Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children--50 to 75 percent--have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.

This item is Non-Returnable

Details

  • ISBN-13: 9780309107426
  • ISBN-10: 0309107423
  • Publisher: National Academies Press
  • Publish Date: September 2008
  • Dimensions: 8.9 x 5.7 x 0.2 inches
  • Shipping Weight: 0.17 pounds
  • Page Count: 64

Related Categories

You May Also Like...

    1

BAM Customer Reviews